Long Non Coding Rnas In Breast Cancer Prevention And Treatment

This volume, with contributions from the most recognized experts in preventive strategies in breast cancer, presents the accepted as well as the novel ideas that have been introduced for the prevention of breast cancer. There is no single preventive agent that can stop the incidence of breast cancer—the malignant disease most frequently diagnosed in women of all races and nationalities. Furthermore, its incidence around the globe is increasing in industrialized countries. The worldwide incidence of breast cancer has increased 30-40% since the 1970s, reaching an excess of 1,390,000 new cases and a mortality of more than 460,000 cases in 2015. Therefore, what is needed is the development of rational strategies for the prevention of this fatal disease.

This book will provide the latest advances in molecular and cellular biology for establishing the foundation of a complete understanding of the mechanisms of breast differentiation leading to cancer prevention. The authors are based on the epidemiological evidence indicating that early first full term pregnancy is a protective factor in human against breast cancer and they have used this paradigm and developed experimental systems in both in vivo and in vitro that have demonstrated mechanistically how the differentiation at the organ and cellular level takes place. This knowledge has provided the blueprint for developing better understanding of the basis of cancer prevention. The transcriptoma analysis of the breast of pre and post-menopausal women has established a genomic signature imprinted in the breast that differs according to the reproductive history of the woman showing that early first full term pregnancy reprogram the organ. This reprogramming takes place at the chromatin level by changing the transcriptional process. The modification of the transcriptional control is due to the expression of non coding RNA sequences and posttranscriptional control driven by the splicesome. The plasticity of the genome of the human breast make possible this reprogramming that is not only induced by the physiological process of pregnancy but by the use of hormones that mimic pregnancy without pregnancy. The author have established the basis of clinical trials for prevention and the discovery that short 15aa peptides of the chorionic gonadotropin hormone can be used in human breast cancer prevention based on preclinical and clinical data.

The book conveys a comprehensive knowledge of long and short ncRNAs in cancer regulation and their potentials as diagnostic biomarkers and therapeutic targets. Topics covered include the molecular mechanisms of various classes of ncRNAs (with emphasis on long non-coding RNAs and microRNAs) in cancer, the functional roles of ncRNAs in regulating different cancer hallmarks (including proliferation, apoptosis, stem-cell properties, epithelial-mesenchymal transition, metabolism, angiogenesis, tumor-host interactions and therapeutic resistance), the role of ncRNAs in regulating cancer signaling circuitry programs (highlighting their involvement in c-myc, p53 and NFkB signaling), a systemic summary of clinical and preclinical studies that evaluate the potential of ncRNA signatures for cancer diagnosis and prognosis and strategies to delivery short ncRNAs as therapeutic molecules for cancer treatment. This book may serve as a comprehensive resource for researchers, graduate students and oncologists in ncRNA and cancer research and help drug development by identifying ncRNA targets.

lncRNAs (long non-coding RNAs) are the relatively longer (more than 200 nucleotides long) subtypes of ncRNAs (non-coding RNAs) i.e the RNAs that do not code for any proteins. However, even without themselves being translated, lncRNAs impact the cellular gene expressions and functions in ways that are just beginning to be explored. The metastasis of human cancers as well as acquired resistance against the administered therapeutics are two major factors responsible for the cancer-associated mortality.

The discovery of microRNAs and its role as gene expression regulators in human carcinogenesis represents one of the most important scientific achievements of the last decade. More recently, other non-coding RNAs have been discovered and its implications in cancer are emerging as well, suggesting a broader than anticipated involvement of the non-coding genome in cancer. Moreover, completely new and unexpected functions for microRNAs are being revealed, leading to the identification of new anticancer molecular targets. This book represents a comprehensive guide on non-coding RNAs and cancer, spanning from its role as cancer biomarkers, to providing the most useful bioinformatic tools, to presenting some of the most relevant discoveries, which indicates how these fascinating molecules act as fine orchestrators of cancer biology.